Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?

Biotech Giants: A Decade of SG&A Cost Strategies

__timestampCelldex Therapeutics, Inc.Cytokinetics, Incorporated
Wednesday, January 1, 20142062200017268000
Thursday, January 1, 20153383700019667000
Friday, January 1, 20163597900027823000
Sunday, January 1, 20172500300036468000
Monday, January 1, 20181926900031282000
Tuesday, January 1, 20191542600039610000
Wednesday, January 1, 20201445600052820000
Friday, January 1, 20212048800096803000
Saturday, January 1, 202227195000177977000
Sunday, January 1, 202330914000173612000
Loading chart...

Unlocking the unknown

SG&A Cost Management: A Tale of Two Biotechs

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, Cytokinetics, Incorporated and Celldex Therapeutics, Inc. have shown contrasting approaches to SG&A cost management. From 2014 to 2023, Cytokinetics saw a staggering 900% increase in SG&A expenses, peaking in 2022 with a 178 million dollar expenditure. In contrast, Celldex's SG&A costs grew by a modest 50% over the same period, reaching a high of 36 million dollars in 2016. This disparity highlights Cytokinetics' aggressive investment in administrative functions, possibly reflecting a strategic push for growth. Meanwhile, Celldex's more conservative spending suggests a focus on cost efficiency. As these companies navigate the biotech landscape, their SG&A strategies will continue to play a pivotal role in their financial trajectories.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025